{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"萌喵读文献-肿瘤学","title":"今日肿瘤学最高分文献 - 2025-03-06","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/570cc277\"></iframe>","width":"100%","height":180,"duration":4,"description":"欢迎收听最新一期的医学突破播客！今天，我们将聚焦2024年小细胞肺癌（SCLC）治疗领域的重大进展。这项研究为我们带来了希望，特别是在免疫疗法领域，通过durvalumab、tarlatamab和lurbinectedin等新疗法，患者的生存期得到了显著延长，有望实现长期生存。此外，精准医学的应用和生物标志物选择的可行性也在推动SCLC治疗的个性化。最后，新成立的倡导团体Small Cell SMASHERS为患者提供了更多支持。这标志着SCLC治疗革命的到来，开启了对抗这一致命疾病的新时代。不要错过，让我们一起探索这些激动人心的发现！","thumbnail_url":"https://img.transistorcdn.com/3WX36CzvFOrNjlF7WfWjzS4HdcMIMmzMs2bmPS-ejLU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83NDNm/MjQ1N2E5NjhjMzVj/NjM0ZTA3YzY2NDE2/ZmIyMi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}